Clinical Utility of the Combined Use of CA19-9 and DUPAN-2 in Pancreatic Adenocarcinoma.
Tatsuaki SumiyoshiKenichiro UemuraRyuta ShintakuyaKenjiro OkadaKenta BabaTakumi HaradaMasahiro SerikawaYasutaka IshiiShinya NakamuraKoji ArihiroYoshiaki MurakamiShinya TakahashiPublished in: Annals of surgical oncology (2024)
Only patients with normal CA19-9 and DUPNA-2 values should be diagnosed with early-stage PDAC.